In this work, the discovery and description of PF‐07321332, a major bioavailable oral SARS‐
CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent …

The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus …

Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …

Background Timely, accurate, and comprehensive estimates of SARS-CoV-2 daily infection
rates, cumulative infections, the proportion of the population that has been infected at least …

As the SARS-CoV-2 pandemic remains uncontrolled owing to the continuous emergence of
variants of concern, there is an immediate need to implement the most effective antiviral …

Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …

The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

Treatment of SARS-CoV-2 targeting its RNA dependent RNA polymerase (RdRp) is of
current interest. Remdesivir has been approved for the treatment of COVID-19 around the …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there have
been multiple peaks of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus …